Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Findings: RCTSemaglutide vs Placebo for Alcohol Use Disorder in Adults, JAMA Psychiatry (2025) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=48 | length = 9 weeks) in non-treatment-seeking adults with alcohol use disorder Treatment: Semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) vs Placebo Primary outcome: Objective alcohol self-administration (at baseline and between Weeks 8 and 9) measured as follows: a standardized procedure was used to estimate voluntary alcohol consumption and ability to delay drinking
widely prescribed and very effective
The European Medicines Agencys June 2025 recognition of NAION as a very rare side effect of semaglutide strengthens these claims by providing regulatory acknowledgment of the vision loss connection
Carmody J, Olendzki B, Reed G, Andersen V, Rosenzweig P
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
Citrus flavonoids and their antioxidant evaluation
Health" loading="lazy"/>
US$ 28.02
US$ 21.40
US$ 27.57
US$ 29.18
US$ 23.51
US$ 26.97
